dissemination still have a poor prognosis [1] ; most of these patients die within 6 months of diagnosis, while the 5-year survival rate is nil [2, 3] .
Introduction
Advances in early diagnosis and surgical techniques have improved the outcome of treatment for gastric cancer. However, gastric cancer patients with peritoneal showing some clinical improvement following this combined chemotherapy and to perform surgical resection for patients in whom peritoneal metastasis had disappeared. In this study, patients with peritoneal dissemination or positive lavage cytology were defi ned as patients with peritoneal metastasis, because patients with positive lavage cytology show a poor prognosis even when curative resection for gastric cancer is performed -the same as that shown for patients with peritoneal dissemination [15, 16] .
This study examined the safety and effi cacy of chemotherapy for peritoneal dissemination as a prospective pilot study.
Patients and methods

Patients
Patients were enrolled in this study between June 2003 and August 2007. Eligible patients had histologically proven peritoneal dissemination (macroscopic peritoneal metastasis) or cytologically confi rmed positive peritoneal lavage cytology (microscopic peritoneal metastasis) from gastric adenocarcinoma on staging laparoscopy. Patients with distant metastasis such as liver metastasis and/or bulky lymph node metastasis adjacent to the common hepatic artery, left gastric artery, and/or celiac axis were excluded, because such patients should receive chemotherapy as a fi rst line of treatment regardless of peritoneal metastasis.
Other inclusion criteria were as follows: age 20-75 years; Eastern Clinical Oncology Group performance status of 0-1; hemoglobin more than 10.0 g/dl; white blood cell count 4000 mm 3 or more; neutrophil count 2000 mm 3 or more; platelet count 100 000 mm 3 or more; aspartate aminotranferase (AST) and alanine aminotransferase (ALT) less than 100 U/l; serum bilirubin 1.5 mg/dl or less; serum creatinine 1.2 mg/dl or less (our upper institutional limit); normal electrocardiogram; and the absence of other severe medical conditions or synchronous malignancy.
Exclusion criteria were as follows: infection or suspected infection, with fever; congestive heart failure; uncontrolled angina pectoris or arrhythmia; uncontrolled diabetes or hypertension; interstitial pneumonia or lung fi brosis; symptomatic brain metastasis; and pregnancy. Patients with a history of prior chemotherapy were also excluded.
Informed consent was obtained from each patient before study entry.
Laparoscopy
Laparoscopy was performed under general anesthesia as an independent procedure by the method we reported previously [17] . After close examination of the peritoneal cavity, peritoneal lavage cytology was performed in the Douglas pouch and left subphrenic space. If there were any suspected metastatic lesions, biopsy of the lesions was performed for histological examination.
After the chemotherapy was completed, conventional examinations were carried out to assess the clinical response; the assessment was done according to the Japanese classifi cation of gastric carcinoma, 2nd English edition [18] and the Japanese clinical criteria for accessment of response to nonsurgical treatment of gastric cancer [19] . If the treatment was judged to have induced a partial response or minimal response with clinical benefi t, such as an increase in appetite and amelioration of abdominal symptoms, second-look laparoscopy was performed to assess the effectiveness of the treatment against peritoneal metastasis (Fig. 1) . Treatment schedules S-1 was administered orally at 80 mg/m 2 for 14 consecutive days, followed by 7 days' rest, as one course. Paclitaxel was administered intravenously, at a dose of 120 mg/m 2 in 500 ml of normal saline, given over a 30-min period, on day 1, following premedication with dexamethasone 8 mg and ranitidine hydrochloride 50 mg, given as a intravenous infusion 60 min prior to paclitaxel administration. This 3-week treatment cycle was repeated fi ve times.
Objective responses and toxicities
The extent of disease was evaluated by physical examination, chest X-ray, computed tomography (CT), upper gastrointestinal series (UGI), and endoscopic examination of the upper gastrointestinal tract before entry into the study and after treatment. Blood cell counts and hepatic and renal function tests were conducted at least once every 3 weeks during the chemotherapy courses.
As the clinical response could not be objectively evaluated according to the response evaluation criteria in solid tumors (RECIST), as indicated above, the responses of the primary tumors were evaluated after fi ve cycles of this treatment based on roentgenographic and endoscopic fi ndings, according to the response criteria of the Japanese Gastric Cancer Association [19] . In this study, complete response of peritoneal dissemination was defi ned as confi rmation of both the disappearance of peritoneal dissemination and negative lavage cytology at both second-look laparoscopy and surgery.
The histological effects on the primary tumor were classifi ed into three categories, and grade 1 was further divided into two subcategories according to the Japanese classifi cation of gastric carcinoma. Namely, grade 1, less than two-thirds tumor shrinkage (grade 1a, less than one-third tumor shrinkage; grade 1b, between onethird and two-thirds tumor shrinkage); grade 2, more than two-thirds tumor shrinkage; and grade 3, complete regression.
The National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2 were applied to evaluate adverse drug reactions.
Statistical analysis
Overall survival (OS) was calculated from the fi rst day of the chemotherapy to the date of death from any cause or last follow-up visit in 2009. Analysis of the OS curve was performed using the Kaplan-Meier method. All statistical analyses were performed using SPSS software (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Sixteen patients were entered into this study. Ten patients had peritoneal dissemination and 13 had positive lavage cytology proved by staging laparoscopy; 6 had only positive lavage cytology without peritoneal dissemination. The median age was 66 years (range, 48-73 years). Twelve patients were male and four were female. Patient characteristics are summarized in Table 1 . All patients had nonmeasurable lesions, because patients with measurable lesions had received chemotherapy without staging laparoscopy and had been excluded. Histologically, one patient had intestinal-type adenocarcinoma, and 15 had diffuse-type adenocarcinoma. Table 2 summarizes the clinical courses of all the patients. One of the 16 patients was not evaluable for response because gastrectomy was performed for acute bleeding from the gastric tumor after one course of chemotherapy. Of the 16 patients enrolled, 7 showed a partial response, 7 showed stable disease, and 1 had progressive disease, yielding an intent-to-treat ORR of 43.8%. However, the response rate in the evaluable patients only was 46.7%. Of the 7 patients with stable disease, 5 showed clinical improvement, such as an increase in appetite or a reduction in abdominal symptoms. For the 12 patients with a partial response or stable disease with clinical improvement, second-look laparoscopy was performed to assess the effectiveness of the chemotherapy against peritoneal metastasis. The metastases had disappeared in 4 of 10 patients with peritoneal dissemination, and peritoneal lavage cytology was negative in 5 of 6 patients whose results were previously positive (Fig. 2) . 
Effi cacy and second-look laparoscopy
Adverse reactions
All patients (except for the one who received only one course of chemotherapy because of emergent gastrectomy) were evaluated for toxic effects. The incidences of the main adverse reactions, scored as the highest grade seen per patient during this chemotherapy, are listed in Table 3 . Grade 3 leukopenia was observed in 13.3% (2/15) of the patients, and grade 3 neutropenia in 20.0% (3/15). The incidences of AST, ALT, and bilirubin increases were 20.0%, 20.0%, and 13.3%, respectively. However, except for leucopenia and neutropenia, there was no hematological toxicity of grade 3 or higher in any patient. Alopecia was the most frequent adverse reaction, with an incidence of 100%. Nonhematological toxicities of grade 3 or higher were not observed in any patient (Table  3) . There was no treatment-related death or delayed severe toxicity. 
Surgical treatment and prognosis
We performed elective surgery in 9 patients in whom peritoneal dissemination had disappeared and/or lavage cytology had become negative on second-look laparoscopy.
The procedures performed are listed in Table 2 . Four patients underwent total gastrectomy with lymph node dissection and four underwent distal gastrectomy, and one underwent gastrojejunostomy because of invasion of the pancreatic head. Apart from these patients, one patient received an emergency total gastrectomy for bleeding.
At the time of surgery, disappearance of peritoneal dissemination was diagnosed in 4 of 10 patients by based on several histological examinations (e.g., presence or absence of white scar on the peritoneum), and negative peritoneal lavage cytology was diagnosed in 2 of 6 patients who had been positive at the time of surgery. The disappearance of peritoneal metastasis was eventually confi rmed in 37.5% of the patients (6/16 cases: 95% confi dence interval [CI], 13.0-62.0; Fig. 2 ).
Pathological examination of the resected specimen demonstrated that grade 2 tumor regression was achieved in two patients, grade 1b in one, and grade 1a in fi ve. On the fi nal pathological examination of the resected specimens, one patient was stage IB, one was stage II, three were stage III, and the remaining four were stage IV. in the fi nal pathological examination of resected specimens, In addition to these patients, there were 7 patients including a case with gastrojejunostomy in stage IV whose primary tumor was not resected (Table 2) .
There were no postoperative complications in any patient.
The 1-and 2-year survival rates were 68.8% and 31.3%, respectively, and the MST was 555 days (95% CI, 233-819 days; Fig. 3 ).
Discussion
Although peritoneal dissemination commonly occurs in advanced gastric cancer, it is diffi cult to diagnose preoperatively by routine examinations such as abdominal ultrasonography and CT, except in patients with ascites. Laparoscopy was reported to be an important diagnostic tool for the staging of advanced gastric cancer [20, 21] , and we too have performed it for patients with clinical T3 gastric cancer, by preoperative multidetector row CT since September 2002. Although staging laparoscopy facilitates a more accurate preoperative diagnosis of peritoneal dissemination, there is no standard treatment for peritoneal dissemination.
S-1, developed as an oral drug for the treatment of gastric cancer, has been reported to be effective against advanced and recurrent gastric cancer, including cases of peritoneal dissemination [4] [5] [6] [7] . S-1 has been reported to be more effective than conventional systemic chemotherapy against peritoneal dissemination, because high concentrations of 5-fl uorouracil (5-FU) are selectively transferred to sites of dissemination. This occurs because S-1 contains gimeracil [CDHP; an inhibitor of 5-FU metabolic enzymes dihydropyrimidine dehydrogenase (DPD)], and CHDF passes through the peritoneum and disseminated nodes with 5-FU after oral administration of S-1, inhibiting its metabolism of 5-FU, and this inhibition plays an important role in the delivery of 5-FU to peritoneal disseminated cells [22] . Recently, Hosokawa et al. [23] reported that the median survival time of patients with only peritoneal metastasis was 24 months following initial S-1 monotherapy. While S-1 was more effective than conventional chemotherapy against peritoneal dissemination, when it was combined with other anticancer drugs such as cisplatin (CDDP), taxanes, and CPT-11, S-1 increased ORRs and prolonged MST [9] [10] [11] .
The results of the SPIRITS study (S-1 vs S-1+CDDP) proved the superiority of the S-1+CDDP combination over S-1 monotherapy [24] . The rate of response to the combination therapy versus monotherapy was 54% versus 31% (P = 0.0018), and the MST was 13.0 versus 11.0 months (P = 0.0366). Moreover, a subgroup analysis suggested that the presence of peritoneal metastasis was an indication for chemotherapy with S-1 plus CDDP, although the effi cacy for peritoneal dissemination itself has remained unclear.
For patients with peritoneal dissemination, systemic chemotherapy with methotrexate (MTX)/5-FU or intraperitoneal chemotherapy has been performed.
Sequential MTX/5-FU therapy was effective in a phase II trial for advanced gastric cancer [25, 26] . In a Japanese phase II trial of sequential MTX/5-FU for patients with advanced gastric cancer, the response rates were reported to be 23% and 41% with low-and intermediate-dose MTX regimens, respectively [27] . Konishi et al. [28] reported that the MTX/5-FU regimen showed greater effi cacy in patients with the diffuse type of adenocarcinoma than in those with the intestinal type. The response rate of patients with peritoneal dissemination in their study was 23% (6/26) and ascites was eliminated in 8 of 16 patients (50%). Tahara et al. [29] reported that sequential MTX/5-FU therapy for patients with confi rmed peritoneal dissemination was effective, and an objective attenuation of ascites was seen in 13 of 26 patients, including 5 who showed complete disappearance of ascites; the MST and median time to treatment failure were 259 days and 167 days, respectively.
Moreover, in a multicenter phase II trial of sequential MTX/5-FU therapy, the response rate of ascites was 35.1%, although the overall objective response rate was 5.7% [30] . Although sequential MTX/5-FU therapy was effective against advanced gastric cancer with malignant ascites, its overall results have been unsatisfactory.
Recently, some investigators have reported good outcomes with intraperitoneal chemotherapy for peritoneal dissemination [31, 32] . These studies demonstrated that intraperitoneal chemotherapy could deliver a high dose into the peritoneal cavity. As taxanes have a high molecular weight and bulky chemical structure, resulting in a delay in peritoneal clearance and an increase in the time they remain in the peritoneal cavity [33] , they can be exploited in the treatment of gastric cancer with peritoneal dissemination.
We performed a pilot study of combined chemotherapy with both intraperitoneal paclitaxel and oral S-1 for patients with peritoneal metastasis and obtained a good result [34] .
We submitted this protocol to the institutional review board of our hospital for a phase II study in 2003, but were rejected because of several problems concerning expansion of the clinical utilization of intraperitoneal paclitaxel administration in Japan. Therefore, we started the intravenous administration of paclitaxel and oral S-1 as a new trial using the same dose intensity as that used for the intraperitoneal chemotherapy [34] .
Paclitaxel was administered as a single agent every 3 weeks at a dose of 210 mg/m 2 in two phase II trials performed in Japan [35, 36] . Subsequently, however, paclitaxel came to be widely used in a weekly schedule of 80 mg/m 2 in Japan [37, 38] , referring to reports that bone marrow toxicity was mild and manageable when compared to the triweekly schedule, although the weekly paclitaxel was not superior to the triweekly regimen in terms of ORRs. In combinations with S-1, paclitaxel was widely used at a dose of 50 or 60 mg/m 2 in a weekly setting [10, 14, 39] , but the weekly schedule had not yet been approved in Japan at the time that we carried out the present study. Therefore, we selected the triweekly schedule for the administration of paclitaxel. According to the dosage of paclitaxel, this drug was administered weekly at a dose of 50 or 60 mg/m 2 two or three times every 3 or 4 weeks. Therefore, dose intensity per week was calculated as ranging from 33.3 to 45.0 mg/ m 2 . Although we adopted 120 mg/m 2 of paclitaxel to match the dose to that used for intraperitoneal administration in our previous study [34] , our dose intensity of 40 mg/m 2 per week seemed to be suffi ciently high, suggesting that the combination of S-1+paclitaxel resulted in a favorable response rate and MST.
In the present study, the response rate and MST were 44% and 555 days, respectively, comparable with those in the SPIRITS trial [24] and other paclitaxel plus S-1 studies [10, 14] , although differences in response rate preclude direct comparisons because we did not evaluate the response by RECIST.
As patients with measureable metastatic lesions were excluded from the present study, the tumor burden in our study patients was relatively small compared to those in other clinical trials for advanced gastric cancer, including the SPIRITS trial [24] . However, the prognosis in patients with peritoneal dissemination has been reported to be poor regardless of the tumor burden, even in patients with only positive peritoneal lavage cytology [15, 16] . More recently, in some new clinical trials for patients with advanced gastric cancer with macroscopic peritoneal metastasis and/or positive peritoneal cytology without any other distant metastasis, there were some patients with dramatically prolonged survival following the administration of S-1 or other treatments such as intraperitoneal administration of taxanes or intraoperative peritoneal hyperthermic chemotherapy after surgical resection of the primary tumor [32, 34, 40, 41] . These new clinical trials may be able to offer treatment options to patients with peritoneal metastasis.
In the present study, we found that the combination of S-1 and triweekly paclitaxel was feasible even in patients receiving surgical resection. Moreover, the complete response rate for peritoneal metastasis was 37.5% by cytopathological examination both at secondlook laparoscopy and surgery, and radical resections were performed for these fi ve patients who achieved a downstaging of gastric cancer. As it is diffi cult to judge the effectiveness of chemotherapy for peritoneal metastasis solely by routine inspections, it seems that our rate of 37.5% for the disappearance of peritoneal disease may become a reference value.
To obtain clear evidence about fi rst-line chemotherapy for patients with peritoneal metastasis, a randomized clinical trial comparing S-1 plus CDDP and S-1 plus i.v. or i.p. administration of other anticancer agents such as taxanes, is necessary. Moreover, it will be necessary to examine whether or not surgical resection of the primary gastric tumor contributes to the prolongation of survival. Recently, Kodera et al. [37] reported a phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity, in which the MST was 705 days and the 2-year survival rate was 47%. These good results, unlike past results, suggest that, for patients with peritoneal dissemination, radical surgery followed by effective treatment may contribute to an improvement of survival [15, 16] .
The chemotherapy regimen used in the present study is thought to be effective and feasible for patients with peritoneal metastasis from gastric cancer. Because this was a small pilot study, we have planned a phase II study to further clarify the effects and safety of this combination chemotherapy for gastric cancer patients with peritoneal dissemination.
